NeuAc(a2-3)Gal(b1-3)[NeuAc(a2-6)]GlcNAc(b1-3)Gal(b1-4)Glc | 61278-38-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: NeuAc(a2-3)Gal(b1-3)[NeuAc(a2-6)]GlcNAc(b1-3)Gal(b1-4)Glc
• 英文别名: (2R,4S,5R,6R)-5-acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-3-hydroxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
• CAS: 61278-38-4
• 化学式: C₄₈H₇₉N₃O₃₇
• 分子量: 1290.1
• InChiKey: FCIROHDMPFOSFG-LAVSNGQLSA-N

物化性质

• 沸点：
  1678.3±65.0 °C(Predicted)
• 密度：
  1.76±0.1 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -13.4
• 重原子数：
  88
• 可旋转键数：
  25
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  648
• 氢给体数：
  24
• 氢受体数：
  37

文献信息

• DISIALYLLACTO-N-TETRAOSE (DSLNT) OR VARIANTS, ISOMERS, ANALOGS AND DERIVATIVES THEREOF TO PREVENT OR INHIBIT BOWEL DISEASE
  申请人：The Regents of The University of California

  公开号：EP2670399A2

  公开（公告）日：2013-12-11
• US9675649B2
  申请人：——

  公开号：US9675649B2

  公开（公告）日：2017-06-13
• [EN] DISIALYLLACTO-N-TETRAOSE (DSLNT) OR VARIANTS, ISOMERS, ANALOGS AND DERIVATIVES THEREOF TO PREVENT OR INHIBIT BOWEL DISEASE<br/>[FR] DISIALYLLACTO-N-TÉTRAOSE (DSLNT) OU VARIANTS, ISOMÈRES, ANALOGUES ET DÉRIVÉS ASSOCIÉS, POUR PRÉVENIR OU INHIBER UNE MALADIE INTESTINALE
  申请人：UNIV CALIFORNIA

  公开号：WO2012106665A2

  公开（公告）日：2012-08-09

  The invention provides formulations comprising isolated Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof.
• [EN] COMPOSITIONS COMPRISING ONE OR MORE HMO'S WITH A CORE OF LacNAc-Lac<br/>[FR] COMPOSITIONS COMPRENANT UN OU PLUSIEURS OLH AYANT UN SQUELETTE DE LACNAC-LAC
  申请人：FRIESLANDCAMPINA NEDERLAND BV

  公开号：WO2021191251A1

  公开（公告）日：2021-09-30

  A synthetic composition comprising one or more compounds according to formula (1), or a pharmaceutically acceptable salt, solvate or ester thereof, for use in the modulation of one or more of: i. the cholesterol level; ii. lipolysis; iii. glucose uptake; iv. CD36 receptor activity; wherein the compound of Formula 1 is Yn→D-Gal-β1→3-(Ym→)(Xp→)D-GlcNAc-β1→3-D-Gal-β1→4-(Xq→)-D-Glc (Formula (1)), wherein X is α-L-Fucose (α-L-Fuc), Y is N-acetyl-D-neuraminic acid (Neu5Ac-α-2-), n, m, p, q indicate the number of the monosaccharide residues present in the compound of formula (1) and n is 0 or 1; m is 0 or 1; p is 0 or 1; q is 0 or 1; and n+m+p+q ≥ 1.